Remix to take Nasdaq spot of Passage Bio in reverse merger for mRNA degrader
Remix Therapeutics will go public via reverse merger with Passage Bio, taking its Nasdaq listing alongside a $100M placement as it advances mRNA degrader REM-422 in cancer.
Remix Therapeutics
Private
Remix Therapeutics is a clinical-stage biotechnology company developing small-molecule RNA-targeted therapeutics that modulate RNA processing. The company announced a reverse merger with Passage Bio in 2026 to take Passage's Nasdaq listing while advancing its lead mRNA degrader program.
Company Info
Sector:Biotechnology / RNA Therapeutics / Small Molecule
Headquarters:Cambridge, Massachusetts, USA
Founded:2018
Website:www.remixtx.com/
Upcoming Milestones & Key Dates
TBD 2026
Corporate
Closing of reverse merger with Passage Bio; Nasdaq listing
Clinical Development Pipeline
REM-422
Target: mRNA degrader (MYB / MYBL1)Recent News
Leadership Team
Pete Smith, Ph.D.
Co-Founder and Chief Executive Officer